ELXR · Biohacking Platform
Physician-supervised biohacking, in one subscription.
Biomarker testing, clinical peptides, at-home IV, telehealth and coaching united in one physician-supervised commerce and membership platform.
ELXRtwc2026!Five clinical products. One membership.
80+ marker deep-dive with clinical interpretation.
Physician-prescribed, compounded and shipped.
Concierge NAD+, hydration & recovery drips.
Board-certified physicians, on-demand.
Ongoing protocol adjustment & accountability.
Every protocol is a signature — built from a person's blood work, biomarkers and goals.
High-end, personalized boxes combine western pharmacology with eastern and holistic modalities. Nothing is prescribed on a hunch — every element is chosen against what the labs reveal each member lacks, needs or is optimizing for.
GLP-1s, BPC-157, TB-500, CJC/Ipamorelin — physician-prescribed and compounded.
Cognitive stacks tuned to focus, memory, sleep and mood biomarkers.
Pharma-grade micronutrients dosed to deficiencies flagged in blood panels.
Omega-3, CoQ10, NAD+ precursors, adaptogens — indication-driven.
Practitioner-grade homeopathic formulations for constitutional support.
TCM herbal formulas, Ayurvedic rasayanas — sourced through licensed practitioners.
Mushroom extracts, bio-resonance, breathwork protocols, red light and PEMF.
80+ biomarkers re-tested on cadence — the box reformulates as your numbers move.
A category that's fragmented, growing and premium.
Consumers today coordinate 5–10 disconnected providers, spending $3,000–$5,000/month with no unified protocol. No competitor combines biomarker personalization, clinical peptides, at-home IV, telehealth, and holistic coaching in one physician-supervised subscription.
Global wellness economy
Global biohacking (2025 → 2035)
Peptide therapeutics (2025 → 2034)
Kuwait peptide wedge by 2030
One clinical spine. Four commercial engines.
Med spas, integrative & longevity clinics. Live today.
Employee benefit kits & executive programs.
Brand-building; 1.5× wholesale markup.
Essential $299 · Performance $599 · Elite $999.
Triple board-certified in Internal Medicine, Hematology, and Oncology. Signed exclusive Medical Director agreement — closing one of ELXR's two largest diligence risks.
Active distribution pipeline with Homaizi Pharma across six GCC & Africa markets. Kuwait launched via a ring-fenced OpCo led by Ziad Elessa.
Conservative against the category. Room to run.
| Comparable | Revenue | Valuation | Multiple |
|---|---|---|---|
| Hims & Hers | $2.35B | $3.6B | 1.5× |
| Thorne | $650M | $1.0B | 2× |
| Everlywell | $111M | $1.3B | 12× |
| Oura | $500M | $11B | 22× |
| ELXR · Yr 5 base case | $135M | $406M | 3.0× |
$5M to launch — and scale nationally.
37% for $5M on a $8.5M pre-money valuation. Physician network, pharmacy partnerships and technology stack already in place.